id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-323647-q67fa0m3	Misra, Durga Prasanna	Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates	2020-09-02		.txt	text/plain	6149	288	36	Hydroxychloroquine, methotrexate and colchicine are also being tried at different stages of the ongoing Coronavirus Disease 19 (COVID-19) pandemic for prophylaxis and treatment. The HIBISCUS multicentre multinational trial is evaluating the effect of HCQ (400 mg daily for the duration of pregnancy) compared to placebo, in addition to standard therapy (i.e. preventative dose of low molecular weight heparin with aspirin), on live births in women with primary APS. A related study, the HIBISCUS-T trial, is evaluating the preventative role for recurrent thrombosis in patients with thrombotic APS treated with HCQ or placebo in addition to oral anticoagulation with vitamin K antagonists for 24 months [15] . Clinical trials might also attempt to decipher the potential utility of hydroxychloroquine, methotrexate or colchicine for primary prevention of cardiovascular events in a high risk population, such as those with metabolic syndrome and in individuals with inflammatory arthritides which predispose to greater cardiovascular risk.	./cache/cord-323647-q67fa0m3.txt	./txt/cord-323647-q67fa0m3.txt